(2E)-3-{4-chloro-1-[2-chloro-4-(phenylethynyl)benzyl]-2-methyl-1H-imidazol-5-yl}-N-(pentylsulfonyl)acrylamide | 279251-82-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2E)-3-{4-chloro-1-[2-chloro-4-(phenylethynyl)benzyl]-2-methyl-1H-imidazol-5-yl}-N-(pentylsulfonyl)acrylamide
• 英文别名: (E)-3-(4-chloro-1-(2-chloro-4-(phenylethynyl)benzyl)-2-methylimidazol-5-yl)-N-(1-pentanesulfonyl)-2-propenamide；(E)-3-[5-chloro-3-[[2-chloro-4-(2-phenylethynyl)phenyl]methyl]-2-methylimidazol-4-yl]-N-pentylsulfonylprop-2-enamide
• CAS: 279251-82-0
• 化学式: C₂₇H₂₇Cl₂N₃O₃S
• 分子量: 544.502
• InChiKey: OMTSRQAROKYSGK-FOCLMDBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  89.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1142879A1

  公开（公告）日：2001-10-10

  Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

  提供了通式(I)代表的咪唑类化合物： 其中各符号如说明书中所定义，本发明提供了这些化合物及其盐类，以及含有这些化合物的药物组合物。这些化合物可用于治疗基于降糖作用的可治愈疾病，以及基于 cGMP-PDE 抑制作用、平滑肌松弛作用、支气管扩张作用、血管扩张作用、平滑肌细胞抑制作用和过敏抑制作用的可治愈疾病。
• Concomitant drugs
  申请人：Kayakiri Hiroshi

  公开号：US20050197376A1

  公开（公告）日：2005-09-08

  This invention provides a pharmaceutical agent containing, in combination, a sulfonamide compound and other therapeutic agent, preferably, at least one compound represented by the formula (I): R 1 —SO 2 —NH—CO-A 1 -CH 2 —R 2 [each symbol is as defined in the specification] or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical agent selected from the group consisting of an α-glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide, which has a superior therapeutic effect.

  本发明提供了一种药物制剂，其中含有磺酰胺化合物和其他治疗剂，最好是至少一种由式 (I) 代表的化合物：R 1 -SO 2 -NH-CO-A 1 -CH 2 -R 2 [各符号如说明书中所定义]或其药学上可接受的盐，以及至少一种选自α-葡萄糖苷酶抑制剂、胰岛素促泌剂、磺酰脲类和双胍类的药剂，这些药剂具有更好的治疗效果。
• US7060721B1
  申请人：——

  公开号：US7060721B1

  公开（公告）日：2006-06-13
• [EN] CONCOMITANT DRUGS<br/>[FR] MÉDICAMENTS ASSOCIÉS
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2005082414A2

  公开（公告）日：2005-09-09

  This invention provides a pharmaceutical agent containing, in combination, a sulfonamide compound and other therapeutic agent, preferably, at least one compound represented by the formula (I): R1-SO2-NH-CO-A1-CH2-R2 [each symbol is as defined in the specification] or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical agent selected from the group consisting of an α-glucosidase inhibitor, an insulin secretagogue, a sulfonylurea and a biguanide, which has a superior therapeutic effect.